See more : Perk International Inc. (PRKI) Income Statement Analysis – Financial Results
Complete financial analysis of Sientra, Inc. (SIEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sientra, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Vedanta Limited (VEDL) Income Statement Analysis – Financial Results
- QuidelOrtho Corporation (QDEL) Income Statement Analysis – Financial Results
- Baolingbao Biology Co.,Ltd. (002286.SZ) Income Statement Analysis – Financial Results
- BBX Capital, Inc. (BBXIB) Income Statement Analysis – Financial Results
- ION Geophysical Corporation (IO) Income Statement Analysis – Financial Results
Sientra, Inc. (SIEN)
About Sientra, Inc.
Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products in the United States and internationally. It offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra Round, Sientra Teardrop, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. The company also provides body contouring products; facial and nasal implants; saline filled sizers. It serves to hospitals, surgery centers, plastic surgeons, dermatologists and other specialties. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 90.55M | 80.68M | 71.24M | 83.70M | 68.13M | 36.54M | 20.73M | 38.11M | 44.73M | 35.17M | 10.45M |
| Cost of Revenue | 48.96M | 36.35M | 32.30M | 33.01M | 26.82M | 14.17M | 6.88M | 10.65M | 11.50M | 8.59M | 2.35M |
| Gross Profit | 41.59M | 44.34M | 38.94M | 50.69M | 41.30M | 22.37M | 13.85M | 27.45M | 33.23M | 26.58M | 8.10M |
| Gross Profit Ratio | 45.94% | 54.95% | 54.66% | 60.56% | 60.63% | 61.22% | 66.82% | 72.04% | 74.29% | 75.57% | 77.49% |
| Research & Development | 14.06M | 10.46M | 10.31M | 13.54M | 10.95M | 9.81M | 9.70M | 7.20M | 4.71M | 4.48M | 3.67M |
| General & Administrative | 41.53M | 31.77M | 38.19M | 46.77M | 42.42M | 41.54M | 23.58M | 18.74M | 10.71M | 18.08M | 9.94M |
| Selling & Marketing | 55.05M | 48.46M | 52.55M | 80.19M | 67.72M | 33.91M | 20.61M | 25.76M | 23.60M | 22.23M | 17.92M |
| SG&A | 96.58M | 80.23M | 90.74M | 126.96M | 110.13M | 75.45M | 44.18M | 44.50M | 34.31M | 40.31M | 27.86M |
| Other Expenses | 12.00K | 6.56M | 111.00K | -55.00K | 39.00K | -95.00K | -36.00K | 360.00K | 2.15M | -46.00K | -1.00K |
| Operating Expenses | 110.64M | 90.69M | 101.06M | 140.50M | 121.08M | 85.26M | 53.89M | 51.70M | 39.02M | 44.79M | 31.53M |
| Cost & Expenses | 159.60M | 127.03M | 133.36M | 173.51M | 147.90M | 99.43M | 60.77M | 62.35M | 50.52M | 53.38M | 33.88M |
| Interest Income | 130.00K | 4.00K | 206.00K | 1.41M | 532.00K | 172.00K | 63.00K | 32.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 9.53M | 8.25M | 9.45M | 4.57M | 3.43M | 1.23M | 98.00K | 3.10M | 2.17M | 872.00K | 0.00 |
| Depreciation & Amortization | 6.78M | 10.93M | 4.41M | 9.05M | 3.32M | 3.03M | 1.18M | 318.00K | 275.00K | 280.00K | 288.00K |
| EBITDA | -62.27M | -46.35M | -70.31M | -103.57M | -75.88M | -59.78M | -38.48M | -38.53M | -3.64M | -17.97M | -23.15M |
| EBITDA Ratio | -68.77% | -43.91% | -81.00% | -96.49% | -111.38% | -163.59% | -192.95% | -62.60% | -8.13% | -51.10% | -221.55% |
| Operating Income | -69.05M | -46.35M | -62.12M | -89.81M | -79.77M | -62.89M | -40.03M | -38.53M | -5.79M | -18.21M | -23.43M |
| Operating Income Ratio | -76.26% | -57.45% | -87.19% | -107.30% | -117.10% | -172.10% | -193.08% | -101.10% | -12.93% | -51.77% | -224.29% |
| Total Other Income/Expenses | -4.23M | -16.15M | -4.96M | -16.97M | -2.86M | -1.16M | -71.00K | -2.71M | -26.00K | -918.00K | -1.00K |
| Income Before Tax | -73.69M | -62.50M | -89.91M | -106.78M | -82.63M | -64.05M | -40.11M | -41.23M | -5.81M | -19.13M | -23.43M |
| Income Before Tax Ratio | -81.38% | -77.46% | -126.21% | -127.58% | -121.29% | -175.26% | -193.43% | -108.20% | -12.99% | -54.38% | -224.30% |
| Income Tax Expense | 27.00K | 21.00K | 33.00K | 34.00K | -4.00K | -17.00K | 61.00K | 3.14M | 4.04M | 826.00K | -1.00K |
| Net Income | -73.72M | -62.52M | -89.95M | -106.82M | -82.63M | -64.03M | -40.17M | -41.23M | -5.81M | -19.13M | -23.43M |
| Net Income Ratio | -81.41% | -77.49% | -126.26% | -127.62% | -121.29% | -175.22% | -193.72% | -108.20% | -12.99% | -54.38% | -224.30% |
| EPS | -10.27 | -10.96 | -17.91 | -26.27 | -32.53 | -33.42 | -22.03 | -26.14 | -22.83 | -20.90 | -25.61 |
| EPS Diluted | -10.27 | -10.96 | -17.91 | -26.27 | -32.53 | -33.42 | -22.03 | -26.14 | -22.83 | -20.90 | -25.61 |
| Weighted Avg Shares Out | 7.17M | 5.71M | 5.02M | 4.07M | 2.54M | 1.92M | 1.82M | 1.58M | 254.54K | 915.12K | 915.12K |
| Weighted Avg Shares Out (Dil) | 7.18M | 5.71M | 5.02M | 4.07M | 2.54M | 1.92M | 1.82M | 1.58M | 254.54K | 915.12K | 915.12K |
Sientra Raises $36.5M At 16% Discount From Last Close
Sientra Inc (NASDAQ: SIEN) prices its previously announced underwritten public offering of 5.4 million common shares at $6.75 per share, with gross proceeds of approximately $36.5 million. The offer price represents a discount of 16% from the last close of $7.99.
Sientra Announces Pricing of Public Offering of Common Stock
SANTA BARBARA, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgeons, today announced the pricing of its previously announced underwritten public offering. The Company will...
Sientra Commences Public Offering of Common Stock
SANTA BARBARA, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgeons, today announced that it has commenced an underwritten public follow-on offering of its common...
Why Sientra Stock Is Soaring Today
The company released preliminary results for its fourth quarter.
Sientra Reports Preliminary Fourth Quarter and Full Year 2020 Results
Estimates highest ever Breast Products segment net sales of $17.9 million, representing 40% year over year growth
Sientra, Inc. (SIEN) CEO Ron Menezes on Q3 2020 Results - Earnings Call Transcript
Sientra, Inc. (SIEN) CEO Ron Menezes on Q3 2020 Results - Earnings Call Transcript
Sientra Reports Third Quarter 2020 Financial Results
Reports record Breast Products net sales of $15.3 million, representing 54% sequential growth and 2 1 % year over year growth
Sientra Appoints Ron Menezes as President and Chief Executive Officer
Jeffrey Nugent, Current Chairman and Chief Executive Officer, Announces His Retirement
Sientra to Participate in Upcoming Virtual Investor Conferences
SANTA BARBARA, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a diversified medical aesthetics company, today announced that members of management are scheduled to participate in four upcoming virtual investor conferences. The Company...
Source: https://incomestatements.info
Category: Stock Reports